- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07911319
TiUltra Implant Study
Comparison of Early Healing Dynamics Between NobelActive S TiUltra and NobelReplace CC Ti Unite Implants Using Resonance Frequency Analysis: A Prospective Clinical Study
This prospective clinical study will compare early healing and implant stability between two Nobel Biocare dental implant systems, NobelActive S TiUltra and NobelReplace CC TiUnite. Approximately 30 implants will be randomly assigned to one of the two implant groups and followed for 12 weeks after placement. Implant stability will be assessed using resonance frequency analysis at implant placement and at approximately 2, 4, 6, 8, and 12 weeks. Clinical healing, radiographic findings, and other treatment-related outcomes will also be evaluated during the follow-up period.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Hanae Saito
- Phone Number: 410-706-3646
- Email: hsaito@umaryland.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- University of Maryland School of Dentistry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Male or Female
- Partially edentulous patients
- Healed ridges (≥3 months post-extraction with no history of socket preservation or ridge augmentation)
- Adequate bone volume (no need for major grafting)
- Sites requiring a single unit implant
- Provision of informed consent
Exclusion Criteria:
- Systemic or local disease or condition that would compromise bone metabolism, post-operative healing and/or osseointegration e.g. uncontrolled diabetes with self-reported most recent HbA1C > 8.0 within last six months
- Systemic corticosteroids or any other medication that would influence bone metabolism, post-operative healing, and/or osseointegration
- History of osseous degenerative diseases
- Heavy smoking (>10 cigarettes/day)
- Bisphosphonate/antiresorptive therapy
- uncontrolled periodontal disease
- Irradiated bone
- Previous history of failed implants
- Recently grafted/augmented site (< 1 year)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: TiUnite
|
NobelReplace CC TiUnite dental implant placed according to the manufacturer's recommended surgical protocol. |
|
Experimental: TiUltra
|
NobelActive S TiUltra dental implant placed according to the manufacturer's recommended surgical protocol. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Implant Stability Quotient (ISQ) Measured by Resonance Frequency Analysis (RFA)
Time Frame: Day 0 (implant placement) and Weeks 2, 4, 6, 8, and 12
|
Implant stability will be assessed using an Osstell device/SmartPeg transducer expressed as Implant Stability Quotient (ISQ) values on a scale of 0 to 100. Longitudinal changes in ISQ will be compared between the TiUnite and S-TiUltra implant groups over the 12-week healing period to evaluate differences in implant stability trajectories. |
Day 0 (implant placement) and Weeks 2, 4, 6, 8, and 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Implant Insertion Torque (Ncm)
Time Frame: Day 0 (during implant placement)
|
Insertion torque will be recorded during implant placement and expressed in Newton-centimeters (Ncm). |
Day 0 (during implant placement)
|
|
Change From Baseline in Radiographic Marginal Bone Level (mm)
Time Frame: Day 0 (baseline) and Weeks 6 and 12
|
Marginal bone levels in millimeters (mm) will be assessed using standardized periapical radiographs obtained at implant placement (baseline) and at 6 and 12 weeks after surgery. |
Day 0 (baseline) and Weeks 6 and 12
|
|
Number of Participants With Implant Failure
Time Frame: From Day 0 (implant placement) through Week 12
|
Implant-related complications, including implant failure and marginal bone loss, will be assessed during the 12-week follow-up period. |
From Day 0 (implant placement) through Week 12
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00120517
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.